Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag for Lower-risk MDS With Thrombocytopenia
NCT05392647Phase 2Unknown
- Sponsor
- Tongji Hospital
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of hetrombopag in myelodysplastic syndrome (MDS), sponsored by Tongji Hospital. Status: unknown.
02
Drugs
hetrombopag
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05392647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05392647.